The role of serum brain injury biomarkers in individuals with a mild-to-moderate COVID infection and Long-COVID - results from the prospective population-based COVI-GAPP study

• DOI: 10.1101/2023.02.15.23285972
• Publication Date: 2023-02-16T22:50:11Z
• Authors: Julia Telser; Kirsten Grossmann; Ornella C Weideli; Dorothea Hillmann; Stefanie Aeschbacher; Niklas Wohlwend; Laura Velez; Jens Kuhle; Aleksandra Maleska; Pascal Benkert; Corina Risch; David Conen; Martin Risch; Lorenz Risch
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

AbstractBackgroundDuring and after mild (no hospitalization) or moderate (hospitalization without ICU) SARS-CoV-2 infections, a wide range of symptoms, including neurological disorders have been reported. It is, however, unknown if these neurological symptoms are associated with brain injury and whether brain injury and related symptoms also emerge in patients suffering from Long-COVID. Neuronal biomarkers such as serum neurofilament light chain and glial fibrillary acidic protein can be used to elucidate neuro-axonal and astroglial injuries. We therefore investigated whether these biomarkers are associated with the COVID-19 infection status (mild-to-moderate), the associated symptoms and Long-COVID.MethodsFrom 146 individuals of the general population with a post-acute, mild-to-moderate SARS-CoV-2 infection, serum neurofilament light chain (sNfL; marker of intra-axonal neuronal injury) and serum glial fibrillary acidic protein (sGFAP; marker of astrocytic activation/injury) were measured. Samples were taken before, during and after (five and ten months) a SARS-CoV-2 infection. Individual symptoms and Long-COVID status were assessed using questionnaires.ResultsNeurological symptoms were described for individuals after a mild and moderate COVID-19 infection, however, serum markers of brain injury (sNfL/sGFAP) did not change after an infection (sNfL:P= 0.74; sGFAP:P= 0.24) and were not associated with headache (P= 0.51), fatigue (P= 0.93), anosmia (P= 0.77) and ageusia (P= 0.47). In participants with Long-COVID, sGFAP (P= 0.038), but not sNfL (P= 0.58) significantly increased but was not associated with neurological symptoms.ConclusionNeurological symptoms in individuals after a mild-to-moderate SARS-CoV-2 infection with and without Long-COVID were not associated with brain injury, although there was some astroglial injury observed in Long-COVID patients.FundingThe COVI-GAPP study received grants from the Innovative Medicines Initiative (IMI grant agreement number 101005177), the Princely House of Liechtenstein, the government of the Principality of Liechtenstein, and the Hanela Foundation (Switzerland). None of the funders played a role in the study design, data collection, data analysis, data interpretation, writing of the report, or decision to publish.